Erythrocyte metabolism during renal anemia treatment with recombinant human erythropoietin

International Journal of Artificial Organs

Volumn 27, Issue 11, 2004, Pages 935-942

  Debska Slizien A ^a   Owczarzak, A ^a   Lysiak Szydlowska W ^a   Rutkowski, Bolesław ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Anemia; Erythrocyte metabolism; Eythropoietin; Hemodialysis

Indexed keywords

ADENOSINETRIPHOSPHATE; BLOOD; HEMODIALYZERS; METABOLISM; PATIENT TREATMENT; PHOSPHATES;

ANEMIA; ERYTHROCYTE METABOLISM; EYTHROPOIETIN; HAEMODIALYSIS; HEALTHY VOLUNTEERS; HEMODIALYSIS PATIENT; HUMAN ERYTHROPOIETIN; JANSSEN; MEAN AGES; RENAL ANEMIA;

DIALYSIS;

2,3 DIPHOSPHOGLYCERIC ACID; ACEBUTOLOL; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADENOSINE TRIPHOSPHATE; AMLODIPINE; ASCORBIC ACID; ATENOLOL; CALCIUM; ENALAPRIL; FERRIC HYDROXIDE SUCROSE; FERRITIN; FOLIC ACID; GLYCOLYTIC ENZYME; HEMOGLOBIN; HEXOKINASE; IRON; LACTATE DEHYDROGENASE; METOPROLOL; NITRENDIPINE; PERINDOPRIL; PHOSPHATE; PHOSPHATE BINDING AGENT; PYRIDOXINE; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ADOLESCENT; ADULT; ANEMIA; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; ENZYME ACTIVITY; ERYTHROCYTE METABOLISM; FEMALE; FERRITIN BLOOD LEVEL; GLUCOSE TRANSPORT; HEMATOLOGICAL PARAMETERS; HEMODIALYSIS PATIENT; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; KIDNEY FAILURE; MALE; PHOSPHATE BLOOD LEVEL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; VOLUNTEER;

EID: 12544258202     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880402701105     Document Type: Article

References (30)

1. Eschbach JW. The anemia of chronic renal failure: Pathophysiology and the effect of recombinant erythropoietin. Kidney Int 1989; 35: 134-48.
2. Ceballos-Picot I, Witko-Sarsat V, Merad-Boudia M, et al. Glutanione antioxidant systems as a marker of oxidative stress in chronic renal failure. Free Radic Biol Med 1996; 21: 845-53.
3. Siems WG, Sommerburg O, Grune T. Erythrocyte free radical and energy metabolism. Clin Nephrol 2000; 53 (suppl 1): S9-17.
4. Durak I, Akyol Ö, Basesme E, et al. Reduced erythrocyte defence mechanism against free radical toxicity in patients with chronic renal failure. Nephron 1994; 66: 76-80.
5. Yawata Y, Jacob HS. Abnormal red cell metabolism in patients with chronic uremia: Nature of the defect and its persistence despite adequate hemodialysis. Blood 1975; 45, 2: 231-9.
6. Wallas CH. Metabolic studies on the erythrocytes from patients with chronic renal disease on haemodialysis. II. ATP metabolism. Br J Hematol 1974; 27: 145-52.
7. Corry DB, Tuck ML, Brickman AS, et al. Sodium transport in red blood cells from dialyzed uremic patients. Kidney Int 1986; 29: 1197-202.
8. Dȩbska-Slizień A, Owczarzak A, Biedunkiewicz B, et al. Erythrocyte (RBC) Na,K-ATPase activity in hemodialysis patients receiving erythropoietin (r-EPO). Eur J Clin Invest 1994; 2 (suppl): S127.
9. Boundurant M, Kelley L, Koury MJ. Is erythropoietin a differentiation factor, a mitotic factor, or a survival factor? In: Bauer C, Koch MK, Scigalla P, Wieczoreck L, eds. Erythropoietin, Molecular Physiology and Clinical Applications 1994; 241-53.
10. Dusanter I, Muller O, Sabbah M, et al. Intracellular transduction or erythropoietin signal. In: Bauer C, Koch MK, Scigalla P, Wieczoreck L, eds. Erythropoietin, Molecular Physiology and Clinical Applications 1994; 231-40.
11. Winearls CG. Historical review on the use of recombinant human erythropoietin in chronic renal failure. Nephrol Dial Transplant 1995; 10 (suppl 2): S3-9.
12. Dȩbska-Slizień A, Kabata J, Rutkowski B, et al. Effect of recombinant human erythropoietin (r-EPO) administration on erythropoiesis in dialysis patients. Pol Arch Int Med 1991; 86: 341-50.
13. Sommerburg O, Grune T, Hampl H, et al. Does treatment of renal anemia with recominant human erythropoietin influence oxidative stress in hemodialysis patients. Clin Nephrol 2000; 53 (suppl 1): S21-9.
14. Ludat K. Sommerburg O, Grune T, et al. Oxidation parameters in complete correction of renal anemia. Clin Nephrol 2000; 53 (suppl 1): S31-5.
15. Rutkowski B, Bautembach S, Dȩbska-Slizień A, et al. Der einfluß des erythropoietins (EPO) auf die dielektrischen eingenschaften der erythrozyten bei chronisch hömodialysierten patienten. Nieren-und Hochdrukkrankheiten 1993; 6: 246-9.
16. Rutkowski B, Nowak J, Beutembach S, Dȩbska-Slizień A, et al. Changes in erythrocyte (E) bilayer during erythropoietin (r-Epo) treatment. Curr Ther Nephrol. Milano, Italy: Wichtig Editore 1993: 203-4.
17. Geudeney X, Chanez C, Grenier A, et al. Temperature dependent immunoreactive assay to screen for digoxin like immunoreactive factors. Clin Chem 1991; 37: 1900-4.
18. Land J, Booth R, Berger R, et al. Development of mitochondrial energy metabolism in rat brain. Biochem J 1977; 164: 339-48.
19. Wallas CH. Metabolic studies on red cells from patients with chronic renal disease on hemodialysis. Br J Hematol 1974; 26: 71-8.
20. Fadeche A, Salako L. Abnormal cation composition on transport in erythrocytes from hypertensive patients. Eur J Clin Invest 1979; 9: 369-75.
21. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 1999; 14 (suppl 5): S1-50.
22. Barany P, Peffersson E, Konarski-Svenson JK. Long-term effects on quality of life in hemodialysis patients of correction of anemia with erythropoietin. Nephrol Dial Transplant 1993; 8: 426-32.
23. Pollock CA, Wyndham R, Collett PV, et al. Effect of erythropoietin therapy on the lipid profile in end-stage renal failure. Kidney Int 1994; 45: 897-902.
24. Trzonkowski P, Myśliwska J, Dȩbska-Slizień A, et al. Long-term therapy with recombinant human erythropoietin decreases percentage of CD 152+ lymphocytes in primary glomerulonephritis haemodialysis patients. Nephrol Dial Transplant 2002; 17: 1070-80.
25. Kokot F, Wiȩcek A, Grzeszczak W, et al. Influence of erythropoietin treatment on endocrine abnormalities in haemodialysed patients. Contrib Nephrol 1989; 76: 257-70.
26. Słomińska E, Szołkiewicz M, Smoleński R, et al. High adenine concentration in chronic renal failure and its relation to erythrocyte ATP. Nephron 2002; 91: 286-91.
27. Siems W, Grune T, Hampl H, et al. Changed purine nucleotide concentration and enzyme activities in erithrocytes of haemodialysis patients undergoing erythropoietin therapy. Eur J Clin Biochem 1992; 30: 455-62.
28. Grimes AJ. Normal and abnormal enzymes of the Embden-Meyerhof pathway (excluding puryvate kinase). In: Human red cell metabolism. Blackwell Scientific Publications, 1980: 108-30.
29. Cowley JP, Chazan JA, Metzger JB, et al. Blood rheology and 2,3-diphosphoglycerate levels after erythropoietin treatment. Ann Clin Lab Sci 1993; 23, 1: 24-32.
30. Najean Y, Moynot A, Deschryver F, et al. Kinetics of erythropoiesis in dialysis patients receiving recombinant erythropoietin treatment. Nephrol Dial Transplant 1989; 4: 350-5.